Microbiome is defined as the genetic material of all the microorganisms, such as bacteria, protozoa, viruses and fungi, that live on and inside the human body. Microbiome therapeutics is the process of restoring healthy gut microbiota inside the human body. In the human body, microorganisms reside in saliva, oral mucosa, conjunctiva, gastrointestinal tract (GIT) and even on the skin. These microorganisms are beneficial for human beings as it helps to balance good health. The study of microbiome has fascinated researchers remarkably and has gained huge significance post the research initiatives taken by the National Institutes of Health (NIH) of the United States with their research project “The Human Microbiome Project (HMP)”, established in the year 2007 through 2016.
The global microbiome therapeutics market is thriving primarily on account of the growing prevalence of diseases caused due to dysbiosis of microbiota in the gut, along with the growing concerns amongst individuals for the reducing number of beneficial microorganisms in the human body, impacted by the long-term use of antibiotics, growing age and unhealthy lifestyle patterns. The global microbiome therapeutics market is anticipated to grow with a notable CAGR during the forecast period, i.e., 2021-2029. The market is segmented by application into diabetes, Crohn’s disease, clostridium difficile infection (CDI), multiple sclerosis, rheumatoid arthritis, and others. Among these segments, the diabetes segment is anticipated to hold the largest share by the end of 2029 owing to the increasing prevalence of diabetes around the globe, coupled with the growing research and developments on the use of microbiome therapeutics for curing type 2 diabetes. According to the statistics by the Centers for Disease Control and Prevention (CDC), in the year 2018, around 10.5% of the population of the United States had diabetes. Studies have reflected that the gut bacteria play a fundamental role in diseases such as diabetes, especially type 2 diabetes. Type 2 diabetes is largely undiagnosed and is caused due to excessive body weight and physical inactivity. Research on the first human metagenome demonstrated the correlation between certain bacterial genes, specific intestinal bacteria and their respective metabolic pathways with type 2 diabetes (T2D).
Early detection and diagnosis of critical diseases in patients helps to increase the survival rate of the patients. As the presumptive identification of diseases plays a major role in saving lives, researchers are increasingly working on to develop medicines and diagnostics processes that help to detect diseases early. Moreover, with the growing incidences of chronic diseases, such as diabetes, Crohn’s disease, clostridium difficile infection (CDI), multiple sclerosis, and others, there is a rising need amongst individuals for the early detection of these diseases, which is raising the need amongst the researchers to research on advanced biological processes by using technologies, such as microbiome therapeutics, which can be designed for use as a validated target for drug development. CLICK TO DOWNLOAD SAMPLE REPORT
Over the decades, governmental organizations with the support of the Nations, are investing a significant share of their GDP for the research and development of novel drugs. The private healthcare organizations along with the support of the governmental bodies, on the other hand, have developed dedicated team of researchers, who have developed novel drugs and vaccines over the years. Projects such as the HMP have opened the face for the advanced studies on diseases which were once thought to be impossible. Such factors are anticipated to drive the growth of the global microbiome therapeutics market in the coming years.
The research processed by numerous organizations on microbiome therapeutics are currently under different phases of clinical development. Organizations have invested massively in these research processes over the years with hopes for success on their efforts. Yet, the concerns for the failure of the research projects, which would significantly impact their research investments is one of the major factors anticipated to hamper the market growth during the forecast period.
Our in-depth analysis of the global microbiome therapeutics market includes the following segments:
On the basis of regional analysis, the global microbiome therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa regions.
The market for microbiome therapeutics in North America is anticipated to hold the largest market share during the forecast period on account of the presence of numerous established research facilities in the region for the development of novel therapeutics, followed by the rising healthcare expenditure and the presence of a population who are highly conscious with their health. Additionally, presence of several key players in the region, along with the favorable government initiatives for research and development, are some of the factors anticipated to drive the growth of the market in the region.
The global microbiome therapeutics market is further classified on the basis of region as follows:
FREQUENTLY ASKED QUESTIONS
Increasing number of collaborations, along with increasing investments for research for microbiome-based therapeutics are some of the major factors driving the market growth.
The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2021-2029.
The major players in the market are YSOPIA Bioscience, DuPont de Nemours, Inc., ENTEROME SA, 4D pharma plc, BiomX Inc., Ferring B.V., Vedanta Biosciences, Inc., Second Genome Therapeutics, and others.
The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The microbiome therapeutics market is segmented by application, and by region.
The diabetes segment, which is a sub-segment of the application segment, is anticipated to hold the largest market share by 2029 on account of the growing research and developments on the use of microbiome therapeutics for curing type 2 diabetes.
Concerns for the failure on the ongoing research for microbiome therapeutics is one of the major factors estimated to act as barriers to the growth of the market.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization